查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1698161

細胞治療市場－全球產業規模、佔有率、趨勢、機會和預測，按治療類型、治療領域、地區和競爭細分，2020-2030 年

Cell Therapy Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type, By Therapeutic Area, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球細胞治療市場價值為 63 億美元，預計在預測期內將實現強勁成長，到 2030 年的複合年成長率將達到 12.01%。在現代醫學領域，科學與創新的融合催生了曾經被認為是科幻小說的變革性治療方法。其中一項突破性的進步就是細胞療法，這是一種利用活細胞的力量治療多種疾病和病症的尖端醫療方法。全球細胞治療市場正在迅速擴張，為患者帶來了新的希望，並帶來了醫療保健方式的典範轉移。細胞療法涉及將活細胞移植或操縱到患者體內，以刺激受損或患病組織的修復、再生或替換。這些細胞可以來自患者本身（自體）或捐贈者（異體）。細胞療法的治療潛力在於它能夠在細胞層面上針對各種疾病的根本原因，而傳統治療通常專注於症狀管理。近年來，由於細胞治療的良好結果和對細胞生物學日益加深的了解，全球細胞治療市場獲得了巨大的發展動力。

市場概覽
預測期 2026-2030
2024年市場規模 63億美元
2030年市場規模 124.7億美元
2025-2030 年複合年成長率 12.01％
成長最快的領域 腫瘤學
最大的市場 北美洲

關鍵市場促進因素

慢性病和退化性疾病盛行率不斷上升

主要市場挑戰

複雜的監管格局

主要市場趨勢

技術進步

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：細胞療法市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型（自體、同種異體）
    • 依治療領域（腫瘤學、心血管疾病、肌肉骨骼疾病、皮膚科）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美細胞治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第7章：歐洲細胞治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太細胞治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美細胞治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲細胞治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球細胞治療市場：SWOT 分析

第 14 章：競爭格局

  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • Tego Science
  • Atara Biotherapeutics
  • Takeda Pharmaceutical Company Limited
  • Bluebird Bio, Inc.
  • Dendreon Corp..

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 17182

Global Cell Therapy Market was valued at USD 6.30 Billion in 2024 and is anticipated to project formidable growth in the forecast period with a CAGR of 12.01% through 2030. In the realm of modern medicine, the convergence of science and innovation has given rise to transformative treatments that were once considered science fiction. One such groundbreaking advancement is cell therapy, a cutting-edge medical approach that harnesses the power of living cells to treat a range of diseases and conditions. The global cell therapy market is rapidly expanding, offering new hope for patients and creating a paradigm shift in the way healthcare is delivered. Cell therapy involves the transplantation or manipulation of living cells into a patient's body to stimulate the repair, regeneration, or replacement of damaged or diseased tissues. These cells can be sourced from the patient's own body (autologous) or from a donor (allogeneic). The therapeutic potential of cell therapy lies in its ability to target the root causes of various diseases at a cellular level, unlike traditional treatments that often focus on symptom management. The global cell therapy market has gained substantial momentum in recent years due to its promising outcomes and a growing understanding of cellular biology.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.30 Billion
Market Size 2030USD 12.47 Billion
CAGR 2025-203012.01%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Chronic and Degenerative Diseases

The rising prevalence of chronic and degenerative diseases is one of the primary factors fueling the expansion of the Global Cell Therapy Market. In 2020, an estimated 523 million individuals globally were affected by cardiovascular diseases (CVDs), with approximately 19 million fatalities attributed to these conditions. This accounted for nearly 32% of all global deaths and reflected an 18.7% increase in absolute mortality compared to 2010. As conventional treatment methods often fail to provide long-term solutions for these conditions, cell therapy is emerging as a breakthrough alternative, offering regenerative and disease-modifying potential. In 2021, noncommunicable diseases (NCDs) were responsible for at least 43 million deaths worldwide, accounting for 75% of all non-pandemic-related fatalities. Alarmingly, 18 million of these deaths occurred in individuals under the age of 70, with 82% of premature fatalities concentrated in low- and middle-income countries. This growing burden highlights a significant unmet medical need for more effective, accessible, and preventive healthcare solutions, particularly in regions with limited resources. Chronic and degenerative diseases such as cancer, cardiovascular diseases, autoimmune disorders, diabetes, and neurodegenerative conditions pose a significant global healthcare burden. Traditional treatment options, including pharmaceuticals and surgical interventions, often provide only symptom relief rather than disease reversal or regeneration. Cell therapy, particularly stem cell and immune cell-based treatments, offers a transformative approach by promoting tissue regeneration, reducing inflammation, and potentially curing previously untreatable diseases. As the global population ages and chronic disease prevalence rises, demand for more effective, long-term solutions is accelerating investment and adoption of cell therapies.

Key Market Challenges

Complex Regulatory Landscape

One of the foremost challenges in the cell therapy market is navigating the complex and evolving regulatory landscape. Unlike traditional pharmaceuticals, which are based on small molecules, cell therapies involve live cells that interact with the patient's body. This dynamic nature raises unique safety and efficacy concerns, leading to intricate regulatory requirements. Ensuring compliance with these regulations can be time-consuming and resource-intensive, potentially delaying the development and approval process.

Key Market Trends

Technological Advancements

The field of medical science is undergoing a transformative phase, with remarkable breakthroughs occurring at an unprecedented pace. Among these groundbreaking advancements, cell therapy stands out as a beacon of hope, promising revolutionary treatments for a multitude of diseases that were once considered untreatable. As technological innovations continue to accelerate, the cell therapy market is experiencing a rapid expansion, offering new avenues for treating a diverse range of medical conditions. Stem cells, with their unique ability to differentiate into various cell types, have captured the attention of researchers and clinicians alike. Advances in stem cell isolation, manipulation, and differentiation techniques have enabled the development of personalized therapies for conditions ranging from neurodegenerative disorders to cardiovascular diseases. The emergence of precise gene editing tools like CRISPR-Cas9 has revolutionized the field of cell therapy. This technology allows scientists to modify a cell's genetic material, correcting mutations or enhancing desired traits before transplantation. Gene-edited cells offer improved therapeutic potential and reduced risks of immune rejection. Immunotherapies harness the body's immune system to target and destroy disease-causing cells. Chimeric Antigen Receptor (CAR) T-cell therapy, a form of immunotherapy, has shown remarkable success in treating certain types of leukemia and lymphoma. Ongoing research aims to expand the applications of CAR-T therapy to solid tumors and other diseases. Microfluidic devices and automated systems have streamlined the production and manipulation of cells for therapy. These technologies enhance scalability, consistency, and quality control, ensuring that cell-based treatments can be manufactured in large quantities without compromising safety and efficacy. As technology continues to evolve, the cell therapy market is projected to experience exponential growth. The convergence of these technological advancements has propelled the development of novel and effective therapies for conditions that were once considered incurable. From autoimmune diseases to degenerative disorders, the spectrum of diseases that can potentially be addressed through cell therapy continues to expand. However, it's important to note that along with the potential benefits, challenges remain. Safety concerns, regulatory hurdles, and the complexities of manufacturing consistent and viable cell therapies on a large scale are among the issues that need to be addressed to fully realize the potential of this field.

Key Market Players

  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • Tego Science
  • Atara Biotherapeutics
  • Takeda Pharmaceutical Company Limited
  • Bluebird Bio, Inc.
  • Dendreon Corp.

Report Scope:

In this report, the Global Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Therapy Market, By Therapy Type:

  • Autologous
  • Allogenic

Cell Therapy Market, By Therapeutics Area:

  • Oncology
  • Cardiovascular Diseases
  • Musculoskeletal Disorders
  • Dermatology

Cell Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Therapy Market.

Available Customizations:

Global Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Cell Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Autologous, Allogenic)
    • 5.2.2. By Therapeutic Area (Oncology, Cardiovascular Diseases, Musculoskeletal Disorders, Dermatology)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Cell Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By Therapeutics Area
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By Therapeutics Area
    • 6.3.2. Canada Cell Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By Therapeutics Area
    • 6.3.3. Mexico Cell Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By Therapeutics Area

7. Europe Cell Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By Therapeutics Area
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cell Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By Therapeutics Area
    • 7.3.2. United Kingdom Cell Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By Therapeutics Area
    • 7.3.3. Italy Cell Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By Therapeutics Area
    • 7.3.4. France Cell Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By Therapeutics Area
    • 7.3.5. Spain Cell Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By Therapeutics Area

8. Asia-Pacific Cell Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By Therapeutics Area
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cell Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By Therapeutics Area
    • 8.3.2. India Cell Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By Therapeutics Area
    • 8.3.3. Japan Cell Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By Therapeutics Area
    • 8.3.4. South Korea Cell Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By Therapeutics Area
    • 8.3.5. Australia Cell Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By Therapeutics Area

9. South America Cell Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By Therapeutics Area
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cell Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By Therapeutics Area
    • 9.3.2. Argentina Cell Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By Therapeutics Area
    • 9.3.3. Colombia Cell Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By Therapeutics Area

10. Middle East and Africa Cell Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By Therapeutics Area
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cell Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By Therapeutics Area
    • 10.3.2. Saudi Arabia Cell Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By Therapeutics Area
    • 10.3.3. UAE Cell Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By Therapeutics Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Cell Therapy Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Novartis AG
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Gilead Sciences, Inc.
  • 14.3. Bristol-Myers Squibb Company
  • 14.4. Johnson & Johnson Services, Inc
  • 14.5. JCR Pharmaceuticals Co., Ltd.
  • 14.6. Tego Science
  • 14.7. Atara Biotherapeutics
  • 14.8. Takeda Pharmaceutical Company Limited
  • 14.9. Bluebird Bio, Inc.
  • 14.10.Dendreon Corp..

15. Strategic Recommendations

16. About Us & Disclaimer